486 related articles for article (PubMed ID: 32627031)
1. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
You W; Shang B; Sun J; Liu X; Su L; Jiang S
Oncol Rep; 2020 Aug; 44(2):424-437. PubMed ID: 32627031
[TBL] [Abstract][Full Text] [Related]
2. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
3. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
4. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
6. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
7. Predicting immunotherapy response through genomics.
Cormedi MCV; Van Allen EM; Colli LM
Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of PD‑L1 in colorectal cancer (Review).
Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
[TBL] [Abstract][Full Text] [Related]
9. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
10. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
[TBL] [Abstract][Full Text] [Related]
12. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Li S; Zhang C; Pang G; Wang P
Front Immunol; 2020; 11():603157. PubMed ID: 33178229
[TBL] [Abstract][Full Text] [Related]
13. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Zhang S; Bai X; Shan F
Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
[TBL] [Abstract][Full Text] [Related]
15. Firing Up Cold Tumors.
Cheng WC; Ho PC
Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
17. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
[TBL] [Abstract][Full Text] [Related]
18. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
19. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
20. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
